Research & Education

Radiation Webinar - Advances in Radiation Therapy

Friday, September 25, 2015 - 6 p.m. Japan Standard Time / 11 a.m. Central European Summer Time

The IASLC Education Committee is pleased to announce the second program in the 2015 series of Live Webinars presented by the Advanced Radiation Technology Committee. This subcommittee is focused on providing educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Francoise Mornex, MD, PhD and feature presentations by Yong Chan Ahn, MD, PhD and Yasushi Nagata, M.D., Ph.D.

IASLC European Webinar Series - 2015/2016 - Surgical Standards for Non-Small Cell Lung Cancer

September 1, 2015 - 7 p.m. Central European Summer Time

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

EGFR TKIs: What is New?

Wednesday, August 26, 2015 at 9 p.m. Eastern Daylight Time

IASLC continues the Lung Cancer Grand Round Series in 2015 with this LIVE WEBINAR featuring Dr. Lecia Sequist. In this program Dr. Sequist will review the current data about best practices for treatment of stage IV EGFR mutation-positive lung cancer.

Radiation Webinar - Stereotactic Ablative Radiotherapy

Tuesday, July 21, 2015 - 1 p.m. CEST - Recording Available

The IASLC Education Committee is pleased to announce the second program in the 2015 series of Live Webinars presented by the Advanced Radiation Technology Committee. This subcommittee is focused on providing educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Francoise Mornex, MD, PhD and feature presentations by Dr. David Palma and Professor Suresh Senan.

Combined Treatment - Stage III NSCLC

Monday, July 20, 2015 - 8 p.m. EDT - Recording Available

This seminar will inform participants the outcomes of concurrent chemo-radiotherapy from two phase III randomized trials, which together enrolled more than 1,100 patients. With these results, the focus is now geared towards investigational approaches that merit evaluation in future clinical trials.

IASLC European Webinar Series - 2015/2016 - Biomarkers and Personalized Medicine for Patients with Lung Cancer

Thursday, July 14, 2015 - 6 p.m. BST - Recording Available

In this session, Prof. Keith Kerr updates a webinar first presented last year, on developments in personalized medicine for patients with lung cancer, the impact that this has had, and could have in the future, for those patients, and how the pursuit of biomarkers to predict response to targeted therapy has changed lung cancer diagnostics.

Radiation Webinar - Making Progress in Stage III NSCLC Management

Thursday, July 9, 2015 - 6 p.m. AEST / 10 a.m. CEST - Recording Available

The IASLC Education Committee is pleased to announce the continuation of a series of Live Webinars presented by the Advanced Radiation Technology Committee. This subcommittee is focused on providing educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Francoise Mornex, MD, PhD and feature presentations by Professor David Ball and Professor Michael Mac Manus

Current Role of Immunotherapy for Lung Cancer

Thursday, June 25, 2015 at 9 p.m. Eastern Time

In this special report, Dr. Scott Gettinger provides an in-depth look at the evolving role of immunotherapeutics in the clinical management of advanced non small cell lung cancer. The most recent data from the 2015 Annual Meeting of the American Society of Clinical Oncology will be highlighted.

The evolving role of PD-1/PD-L1 inhibitors in the clinical management of non-small cell lung cancer

Wednesday, June 10, 2015 9:00 pm Eastern Time

This presentation will inform the participant about emerging data regarding inhibitors of PD-1 and PD-L1. Agents discussed will include those that are FDA approved for non-small cell lung cancer, as well as those for which there is data available but no current approval. Topics to be addressed will include data with respect to efficacy, safety, and proposed approaches to select patients most likely to have clinical benefit with these agents

New Therapies Are Coming for Malignant Pleural Mesothelioma - 14th Webinar: IASLC Lung Cancer Grand Rounds Series

Recording Available

IASLC is holding a LIVE WEBINAR featuring Dr. Lee Krug. This session will begin with a discussion regarding the current standard approach for evaluation and treatment of a patient with malignant pleural mesothelioma.

Pages